Congress bans federal research on gender-affirming medical treatments—eliminating evidence for infor
H.R. 10127 — TRANS Government Research Act · Filed by Nancy Mace (R-SC) · Introduced Aug 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits the use of all federal research funding for studies examining the effects of gender-affirming medical treatments (including surgeries, hormone therapy, and puberty blockers). It defines these treatments narrowly by biological sex and reproductive capacity, and bars any federally funded research that studies their outcomes, safety, efficacy, or health impacts.
Why we flagged it
The bill's operative mechanism is a categorical ban on federal research funding based on the subject matter of the research, not on scientific merit, methodology, or public-health justification. The acronym-based title (TRANS Government Research Act) signals that the bill's primary purpose is ideological messaging rather than evidence-based policy.
What the text implies
- The definition of 'covered research' is so broad it may capture epidemiological studies, safety monitoring, long-term outcome tracking, and comparative-effectiveness research—not just advocacy research. Any study examining health outcomes in this population becomes unfundable.
- The bill does not distinguish between research on minors and adults, or between research on safety vs. efficacy vs. social outcomes. A study on adverse events or treatment complications would be equally prohibited.
The full analysis lists 4 implications of this text.
Who it affects
Citizens lose access to federally funded research on the effects of a category of medical treatments, reducing evidence available for informed medical decision-making, clinical practice, and public health policy. The prohibition applies regardless of research quality, methodology, or public-health value, and eliminates a primary source of independent evidence on treatment outcomes.